Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

How to manage children who have come into contact with patients affected by tuberculosis.

Lancella L, Vecchio AL, Chiappini E, Tadolini M, Cirillo D, Tortoli E, de Martino M, Guarino A, Principi N, Villani A, Esposito S, Galli L; Italian Pediatric TB Study Group.

J Clin Tuberc Other Mycobact Dis. 2015 Aug 8;1:1-12. doi: 10.1016/j.jctube.2015.07.002. eCollection 2015 Nov. Review.

PMID:
31723675
2.

TB consilia and quality of tuberculosis management.

Pontali E, Tadolini M, Migliori GB.

Int J Tuberc Lung Dis. 2019 Oct 1;23(10):1048-1049. doi: 10.5588/ijtld.19.0423. No abstract available.

PMID:
31627767
3.

A multidrug resistant tuberculosis case treated with continuous infusion of meropenem in outpatient care.

Vanino E, Tadolini M, Attard L, Cascavilla A, Pea F, Viale P.

Int J Tuberc Lung Dis. 2019 Sep 1;23(9):1042. doi: 10.5588/ijtld.18.0829. No abstract available.

PMID:
31615614
4.

Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report.

Borisov S, Danila E, Maryandyshev A, Dalcolmo M, Miliauskas S, Kuksa L, Manga S, Skrahina A, Diktanas S, Codecasa LR, Aleksa A, Bruchfeld J, Koleva A, Piubello A, Udwadia ZF, Akkerman OW, Belilovski E, Bernal E, Boeree MJ, Loidi JC, Cai Q, Cebrian Gallardo JJ, Dara M, Davidavičienė E, Forsman LD, De Los Rios Jefe J, Denholm J, Drakšienė J, Duarte R, Elamin SE, Salinas NE, Ferrarese M, Filippov A, Garcia A, García-García JM, Gaudiesiute I, Gavazova B, Gayoso R, Rosso RG, Gruslys V, Gualano G, Hoefsloot W, Jonsson J, Khimova E, Kunst H, Laniado-Laborín R, Li Y, Magis-Escurra C, Manfrin V, Marchese V, Robles EM, Matteelli A, Mazza-Stalder J, Moschos C, Munoz-Torrico M, Hamdan HM, Nakčerienė B, Nicod L, Marcos MN, Palmero DJ, Palmieri F, Papavasileiou A, Payen MC, Pontarelli A, Quirós S, Rendon A, Saderi L, Šmite A, Solovic I, Souleymane MB, Tadolini M, van den Boom M, Vescovo M, Viggiani P, Yedilbayev A, Zablockis R, Zhurkin D, Zignol M, Visca D, Spanevello A, Caminero JA, Alffenaar JW, Tiberi S, Centis R, D'Ambrosio L, Pontali E, Sotgiu G, Migliori GB.

Eur Respir J. 2019 Oct 10. pii: 1901522. doi: 10.1183/13993003.01522-2019. [Epub ahead of print]

PMID:
31601711
5.

QuantiFERON-TB Performs Better in Children, Including Infants, than in Adults with Active Tuberculosis: a Multicenter Study.

Lombardi G, Pellegrino MT, Denicolò A, Corsini I, Tadolini M, Bergamini BM, Meacci M, Garazzino S, Peracchi M, Lanari M, Re MC, Dal Monte P.

J Clin Microbiol. 2019 Sep 24;57(10). pii: e01048-19. doi: 10.1128/JCM.01048-19. Print 2019 Oct.

PMID:
31391228
6.

Predictors of time to sputum smear conversion in patients with pulmonary tuberculosis under treatment.

Bisognin F, Amodio F, Lombardi G, Bacchi Reggiani ML, Vanino E, Attard L, Tadolini M, Re MC, Dal Monte P.

New Microbiol. 2019 Jul;42(3):171-175. Epub 2019 Jun 3.

7.

Reducing tuberculosis transmission: a consensus document from the World Health Organization Regional Office for Europe.

Migliori GB, Nardell E, Yedilbayev A, D'Ambrosio L, Centis R, Tadolini M, van den Boom M, Ehsani S, Sotgiu G, Dara M.

Eur Respir J. 2019 Jun 5;53(6). pii: 1900391. doi: 10.1183/13993003.00391-2019. Print 2019 Jun.

PMID:
31023852
8.

Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study.

Akkerman O, Aleksa A, Alffenaar JW, Al-Marzouqi NH, Arias-Guillén M, Belilovski E, Bernal E, Boeree MJ, Borisov SE, Bruchfeld J, Cadiñanos Loidi J, Cai Q, Caminero JA, Cebrian Gallardo JJ, Centis R, Codecasa LR, D'Ambrosio L, Dalcolmo M, Danila E, Dara M, Davidavičienė E, Davies Forsman L, De Los Rios Jefe J, Denholm J, Duarte R, Elamin SE, Ferrarese M, Filippov A, Ganatra S, Garcia A, García-García JM, Gayoso R, Giraldo Montoya AM, Gomez Rosso RG, Gualano G, Hoefsloot W, Ilievska-Poposka B, Jonsson J, Khimova E, Kuksa L, Kunst H, Laniado-Laborín R, Li Y, Magis-Escurra C, Manfrin V, Manga S, Marchese V, Martínez Robles E, Maryandyshev A, Matteelli A, Migliori GB, Mullerpattan JB, Munoz-Torrico M, Mustafa Hamdan H, Nieto Marcos M, Noordin NM, Palmero DJ, Palmieri F, Payen MC, Piubello A, Pontali E, Pontarelli A, Quirós S, Rendon A, Skrahina A, Šmite A, Solovic I, Sotgiu G, Souleymane MB, Spanevello A, Stošić M, Tadolini M, Tiberi S, Udwadia ZF, van den Boom M, Vescovo M, Viggiani P, Visca D, Zhurkin D, Zignol M; members of the International Study Group on new anti-tuberculosis drugs and adverse events monitoring.

Int J Infect Dis. 2019 Jun;83:72-76. doi: 10.1016/j.ijid.2019.03.036. Epub 2019 Apr 3.

9.

Challenging MDR-TB clinical problems - The case for a new Global TB Consilium supporting the compassionate use of new anti-TB drugs.

Tiberi S, Pontali E, Tadolini M, D'Ambrosio L, Migliori GB.

Int J Infect Dis. 2019 Mar;80S:S68-S72. doi: 10.1016/j.ijid.2019.01.040. Epub 2019 Jan 25.

10.

Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic review.

Pontali E, Sotgiu G, Tiberi S, Tadolini M, Visca D, D'Ambrosio L, Centis R, Spanevello A, Migliori GB.

Eur Respir J. 2018 Jul 4;52(1). pii: 1800934. doi: 10.1183/13993003.00934-2018. Print 2018 Jul. No abstract available.

PMID:
29903862
11.

Overview of fever of unknown origin in adult and paediatric patients.

Attard L, Tadolini M, De Rose DU, Cattalini M.

Clin Exp Rheumatol. 2018 Jan-Feb;36 Suppl 110(1):10-24. Epub 2018 May 3. Review.

12.

Combining bedaquiline and delamanid to treat multidrug-resistant tuberculosis.

Tadolini M, Tiberi S, Migliori GB.

Lancet Infect Dis. 2018 May;18(5):480-481. doi: 10.1016/S1473-3099(18)30106-3. Epub 2018 Feb 13. No abstract available.

PMID:
29452940
13.

Socioeconomic status and biomedical risk factors in migrants and native tuberculosis patients in Italy.

Pittalis S, Piselli P, Contini S, Gualano G, Alma MG, Tadolini M, Piccioni P, Bocchino M, Matteelli A, Bonora S, Di Biagio A, Franzetti F, Carbonara S, Gori A, Sotgiu G, Palmieri F, Ippolito G, Girardi E.

PLoS One. 2017 Dec 18;12(12):e0189425. doi: 10.1371/journal.pone.0189425. eCollection 2017.

14.

Team approach to manage difficult-to-treat TB cases: Experiences in Europe and beyond.

D'Ambrosio L, Bothamley G, Caminero Luna JA, Duarte R, Guglielmetti L, Muñoz Torrico M, Payen MC, Saavedra Herrera N, Salazar Lezama MA, Skrahina A, Tadolini M, Tiberi S, Veziris N, Migliori GB.

Pulmonology. 2018 Mar - Apr;24(2):132-141. doi: 10.1016/j.rppnen.2017.10.005. Epub 2017 Dec 8. Review.

15.

Systematic Tuberculosis Screening in Asylum Seekers in Italy.

Vanino E, Tadolini M, Attard L, Po C, Francia F, Giannini A, Viale P.

Clin Infect Dis. 2017 Oct 15;65(8):1407-1409. doi: 10.1093/cid/cix503.

PMID:
29017255
16.

Delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis in children: a systematic review.

D'Ambrosio L, Centis R, Tiberi S, Tadolini M, Dalcolmo M, Rendon A, Esposito S, Migliori GB.

J Thorac Dis. 2017 Jul;9(7):2093-2101. doi: 10.21037/jtd.2017.06.16. Review.

17.

A new free-cost e-service supporting clinicians to manage their difficult-to-treat tuberculosis cases: The European Respiratory Society-World Health Organization tuberculosis Consilium.

D'Ambrosio L, Tadolini M, Centis R, Chalmers JD, Migliori GB.

Indian J Med Res. 2017 Mar;145(3):261-263. doi: 10.4103/ijmr.IJMR_37_17. No abstract available.

18.

Diagnosis of smear-negative tuberculosis is greatly improved by Xpert MTB/RIF.

Lombardi G, Di Gregori V, Girometti N, Tadolini M, Bisognin F, Dal Monte P.

PLoS One. 2017 Apr 21;12(4):e0176186. doi: 10.1371/journal.pone.0176186. eCollection 2017.

19.

Multidetector CT urography in urogenital tuberculosis: use of reformatted images for the assessment of the radiological findings. A pictorial essay.

Gaudiano C, Tadolini M, Busato F, Vanino E, Pucci S, Corcioni B, Golfieri R.

Abdom Radiol (NY). 2017 Sep;42(9):2314-2324. doi: 10.1007/s00261-017-1129-0. Review.

PMID:
28389790
20.

Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review.

Migliori GB, Pontali E, Sotgiu G, Centis R, D'Ambrosio L, Tiberi S, Tadolini M, Esposito S.

Int J Mol Sci. 2017 Feb 7;18(2). pii: E341. doi: 10.3390/ijms18020341. Review.

21.

Liver transplantation is associated with good clinical outcome in patients with active tuberculosis and acute liver failure due to anti-tubercular treatment.

Bartoletti M, Martelli G, Tedeschi S, Morelli M, Bertuzzo V, Tadolini M, Pianta P, Cristini F, Giannella M, Lewis RE, Pinna AD, Viale P.

Transpl Infect Dis. 2017 Apr;19(2). doi: 10.1111/tid.12658. Epub 2017 Mar 11. Review.

PMID:
28054732
22.

Crossborder travel and multidrugresistant tuberculosis (MDRTB) in Europe.

Matteelli A, Centis R, Sulis G, Tadolini M.

Travel Med Infect Dis. 2016 Nov - Dec;14(6):588-590. doi: 10.1016/j.tmaid.2016.11.017. Epub 2016 Nov 30.

PMID:
27913312
23.
24.

New and Repurposed Drugs for Pediatric Multidrug-Resistant Tuberculosis. Practice-based Recommendations.

Harausz EP, Garcia-Prats AJ, Seddon JA, Schaaf HS, Hesseling AC, Achar J, Bernheimer J, Cruz AT, D'Ambrosio L, Detjen A, Graham SM, Hughes J, Jonckheere S, Marais BJ, Migliori GB, McKenna L, Skrahina A, Tadolini M, Wilson P, Furin J; Sentinel Project on Pediatric Drug-Resistant Tuberculosis.

Am J Respir Crit Care Med. 2017 May 15;195(10):1300-1310. doi: 10.1164/rccm.201606-1227CI. Review.

25.

Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine.

Tadolini M, Lingtsang RD, Tiberi S, Enwerem M, D'Ambrosio L, Sadutshang TD, Centis R, Migliori GB.

Eur Respir J. 2016 Nov;48(5):1527-1529. doi: 10.1183/13993003.01552-2016. No abstract available.

26.

Faster for less: the new "shorter" regimen for multidrug-resistant tuberculosis.

Sotgiu G, Tiberi S, D'Ambrosio L, Centis R, Alffenaar JW, Caminero JA, Abdo Arbex M, Alarcon Guizado V, Aleksa A, Dore S, Gaga M, Gualano G, Kunst H, Payen MC, Roby Arias AJ, Skrahina A, Solovic I, Sulis G, Tadolini M, Zumla A, Migliori GB; International Carbapenem Study Group.

Eur Respir J. 2016 Nov;48(5):1503-1507. doi: 10.1183/13993003.01249-2016. Epub 2016 Sep 1. No abstract available.

27.

First evaluation of QuantiFERON-TB Gold Plus performance in contact screening.

Barcellini L, Borroni E, Brown J, Brunetti E, Campisi D, Castellotti PF, Codecasa LR, Cugnata F, Di Serio C, Ferrarese M, Goletti D, Lipman M, Rancoita PM, Russo G, Tadolini M, Vanino E, Cirillo DM.

Eur Respir J. 2016 Nov;48(5):1411-1419. doi: 10.1183/13993003.00510-2016. Epub 2016 Jul 7.

28.

Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges.

Tadolini M, Garcia-Prats AJ, D'Ambrosio L, Hewison C, Centis R, Schaaf HS, Marais BJ, Ferreira H, Caminero JA, Jonckheere S, Sinha A, Herboczek K, Khaidarkhanova Z, Hayrapetyan A, Khachatryan N, Urtkmelidze Ia, Loreti C, Esposito S, Matteelli A, Furin J, Varaine F, Migliori GB.

Eur Respir J. 2016 Sep;48(3):938-43. doi: 10.1183/13993003.00705-2016. Epub 2016 Jun 23. No abstract available.

29.

First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline.

Tadolini M, Lingtsang RD, Tiberi S, Enwerem M, D'Ambrosio L, Sadutshang TD, Centis R, Migliori GB.

Eur Respir J. 2016 Sep;48(3):935-8. doi: 10.1183/13993003.00637-2016. Epub 2016 Jun 10. No abstract available.

30.

WHO strategies for the programmatic management of drug-resistant tuberculosis.

Matteelli A, Centis R, D'Ambrosio L, Sotgiu G, Tadolini M, Pontali E, Spanevello A, Migliori GB.

Expert Rev Respir Med. 2016 Sep;10(9):991-1002. doi: 10.1080/17476348.2016.1199278. Epub 2016 Jun 22. Review.

PMID:
27276361
31.

Comparison of effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB.

Tiberi S, Sotgiu G, D'Ambrosio L, Centis R, Abdo Arbex M, Alarcon Arrascue E, Alffenaar JW, Caminero JA, Gaga M, Gualano G, Skrahina A, Solovic I, Sulis G, Tadolini M, Alarcon Guizado V, De Lorenzo S, Roby Arias AJ, Scardigli A, Akkerman OW, Aleksa A, Artsukevich J, Auchynka V, Bonini EH, Chong Marín FA, Collahuazo López L, de Vries G, Dore S, Kunst H, Matteelli A, Moschos C, Palmieri F, Papavasileiou A, Payen MC, Piana A, Spanevello A, Vargas Vasquez D, Viggiani P, White V, Zumla A, Migliori GB.

Eur Respir J. 2016 Jun;47(6):1758-66. doi: 10.1183/13993003.00214-2016. Epub 2016 Apr 13.

32.

Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB.

Tiberi S, Payen MC, Sotgiu G, D'Ambrosio L, Alarcon Guizado V, Alffenaar JW, Abdo Arbex M, Caminero JA, Centis R, De Lorenzo S, Gaga M, Gualano G, Roby Arias AJ, Scardigli A, Skrahina A, Solovic I, Sulis G, Tadolini M, Akkerman OW, Alarcon Arrascue E, Aleska A, Avchinko V, Bonini EH, Chong Marín FA, Collahuazo López L, de Vries G, Dore S, Kunst H, Matteelli A, Moschos C, Palmieri F, Papavasileiou A, Spanevello A, Vargas Vasquez D, Viggiani P, White V, Zumla A, Migliori GB.

Eur Respir J. 2016 Apr;47(4):1235-43. doi: 10.1183/13993003.02146-2015. Epub 2016 Mar 10.

33.

Effectiveness and Safety of Imipenem-Clavulanate Added to an Optimized Background Regimen (OBR) Versus OBR Control Regimens in the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis.

Tiberi S, Sotgiu G, D'Ambrosio L, Centis R, Arbex MA, Alarcon Arrascue E, Alffenaar JW, Caminero JA, Gaga M, Gualano G, Skrahina A, Solovic I, Sulis G, Tadolini M, Alarcon Guizado V, De Lorenzo S, Roby Arias AJ, Scardigli A, Akkerman OW, Aleksa A, Artsukevich J, Avchinko V, Bonini EH, Chong Marín FA, Collahuazo López L, de Vries G, Dore S, Kunst H, Matteelli A, Moschos C, Palmieri F, Papavasileiou A, Payen MC, Piana A, Spanevello A, Vargas Vasquez D, Viggiani P, White V, Zumla A, Migliori GB.

Clin Infect Dis. 2016 May 1;62(9):1188-90. doi: 10.1093/cid/ciw088. Epub 2016 Feb 16. No abstract available.

PMID:
26908794
34.

First independent evaluation of QuantiFERON-TB Plus performance.

Barcellini L, Borroni E, Brown J, Brunetti E, Codecasa L, Cugnata F, Dal Monte P, Di Serio C, Goletti D, Lombardi G, Lipman M, Rancoita PM, Tadolini M, Cirillo DM.

Eur Respir J. 2016 May;47(5):1587-90. doi: 10.1183/13993003.02033-2015. Epub 2016 Feb 11. No abstract available.

35.

Recommendations for treating children with drug-resistant tuberculosis.

Galli L, Lancella L, Garazzino S, Tadolini M, Matteelli A, Migliori GB, Principi N, Villani A, Esposito S; Italian Pediatric TB Study Group.

Pharmacol Res. 2016 Mar;105:176-82. doi: 10.1016/j.phrs.2016.01.020. Epub 2016 Jan 26. Review.

PMID:
26821118
36.

Recommendations Concerning the First-Line Treatment of Children with Tuberculosis.

Principi N, Galli L, Lancella L, Tadolini M, Migliori GB, Villani A, Esposito S; Italian Pediatric TB Study Group.

Paediatr Drugs. 2016 Feb;18(1):13-23. doi: 10.1007/s40272-015-0155-z. Review.

PMID:
26612773
37.

Recommendations Concerning the Therapeutic Approach to Immunocompromised Children With Tuberculosis.

Lancella L, Galli L, Chiappini E, Montagnani C, Gabiano C, Garazzino S, Principi N, Tadolini M, Matteelli A, Battista Migliori G, Villani A, de Martino M, Esposito S; Italian Pediatric TB Study Group.

Clin Ther. 2016 Jan 1;38(1):180-90. doi: 10.1016/j.clinthera.2015.10.012. Epub 2015 Nov 6. Review.

PMID:
26548321
38.

Recommendations for the diagnosis of pediatric tuberculosis.

Chiappini E, Lo Vecchio A, Garazzino S, Marseglia GL, Bernardi F, Castagnola E, Tomà P, Cirillo D, Russo C, Gabiano C, Ciofi D, Losurdo G, Bocchino M, Tortoli E, Tadolini M, Villani A, Guarino A, Esposito S; Italian Pediatric TB Study Group.

Eur J Clin Microbiol Infect Dis. 2016 Jan;35(1):1-18. Review.

PMID:
26476550
39.

Compassionate and optimum use of new tuberculosis drugs.

Matteelli A, D'Ambrosio L, Centis R, Tadolini M, Migliori GB.

Lancet Infect Dis. 2015 Oct;15(10):1131-1132. doi: 10.1016/S1473-3099(15)00296-0. Epub 2015 Sep 20. No abstract available.

PMID:
26461941
40.

A new free-cost e-service supporting clinicians to manage their difficult-to-treat TB cases: the ERS-WHO TB consilium.

D'Ambrosio L, Tadolini M, Centis R, Migliori GB.

J Thorac Dis. 2015 Jul;7(7):1080-5. doi: 10.3978/j.issn.2072-1439.2015.07.15. No abstract available.

41.

Supporting clinical management of the difficult-to-treat TB cases: the ERS-WHO TB Consilium.

D'Ambrosio L, Tadolini M, Centis R, Duarte R, Sotgiu G, Aliberti S, Dara M, Migliori GB.

Int J Infect Dis. 2015 Mar;32:156-60. doi: 10.1016/j.ijid.2014.12.024.

42.

The first population-based national tuberculosis prevalence survey in Ethiopia, 2010-2011.

Kebede AH, Alebachew Z, Tsegaye F, Lemma E, Abebe A, Agonafir M, Kebede AJ, Demissie D, Girmachew F, Yaregal Z, Dana F, Getahun M, Fiseha Y, Meaza A, Dirse N, Timimi H, Sismanidis C, Tadolini M, Onozaki I.

Int J Tuberc Lung Dis. 2014 Jun;18(6):635-9. doi: 10.5588/ijtld.13.0417.

PMID:
24903931
43.

ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use.

Esposito S, D'Ambrosio L, Tadolini M, Schaaf HS, Caminero Luna J, Marais B, Centis R, Dara M, Matteelli A, Blasi F, Migliori GB.

Eur Respir J. 2014 Sep;44(3):811-5. doi: 10.1183/09031936.00060414. Epub 2014 May 15. No abstract available.

44.

Trend of microbiologically-confirmed tuberculosis in a low-incidence setting with high immigration rates.

Lombardi G, Dal Monte P, Denicolò A, Tadolini M, Martelli G, Bacchi Reggiani ML, Viale P, Landini MP.

BMC Public Health. 2014 Apr 10;14:340. doi: 10.1186/1471-2458-14-340.

45.

Paediatric tuberculosis in Europe: lessons from Denmark and inclusive strategies to consider.

Marais BJ, Tadolini M, Zignol M, Migliori GB.

Eur Respir J. 2014 Mar;43(3):678-84. doi: 10.1183/09031936.00133613. No abstract available.

46.

Tuberculosis elimination: theory and practice in Europe.

D'Ambrosio L, Dara M, Tadolini M, Centis R, Sotgiu G, van der Werf MJ, Gaga M, Cirillo D, Spanevello A, Raviglione M, Blasi F, Migliori GB; European national programme representatives.

Eur Respir J. 2014 May;43(5):1410-20. doi: 10.1183/09031936.00198813. Epub 2014 Jan 3.

47.

ERS/WHO tuberculosis consilium: reporting of the initial 10 cases.

D'Ambrosio L, Tadolini M, Dupasquier S, Tiberi S, Centis R, Dara M, Blasi F, Migliori GB.

Eur Respir J. 2014 Jan;43(1):286-9. doi: 10.1183/09031936.00125813. Epub 2013 Sep 26. No abstract available.

48.

Do we need a new Fleming époque: The nightmare of drug-resistant tuberculosis.

Sotgiu G, Centis R, D'Ambrosio L, Tadolini M, Castiglia P, Migliori GB.

Int J Mycobacteriol. 2013 Sep;2(3):123-5. doi: 10.1016/j.ijmyco.2013.07.001. Epub 2013 Jul 24.

49.

Human herpesvirus-8-related Kaposi's sarcoma after liver transplantation successfully treated with cidofovir and liposomal daunorubicin.

Verucchi G, Calza L, Trevisani F, Zambruni A, Tadolini M, Giuliani R, Manfredi R, Andreone P, Chiodo F, Bernardi M.

Transpl Infect Dis. 2005 Mar;7(1):34-7.

PMID:
15984947
50.

Rituximab alone proves effective in the treatment of refractory, severe stage III AIDS-related non-Hodgkin's paediatric lymphoma.

Manfredi R, Tadolini M, Fortunato L, Calza L, Marinacci G, Chiodo F.

AIDS. 2003 Sep 26;17(14):2146-8. No abstract available.

PMID:
14502029

Supplemental Content

Loading ...
Support Center